AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday
by Zacks Equity Research
Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.
Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the most recent trading session, Astrazeneca (AZN) closed at $67.35, indicating a +1.28% shift from the previous trading day.
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
by Zacks Equity Research
AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Yes Virginia, There Is a Santa Claus Rally
by Mark Vickery
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod
by Zacks Equity Research
FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
by Kinjel Shah
FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
by Zacks Equity Research
Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the most recent trading session, Astrazeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day.
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
by Kinjel Shah
Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.
The Zacks Analyst Blog Highlights Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources
by Zacks Equity Research
Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources are part of the Zacks top Analyst Blog.
Top Analyst Reports for Adobe, AstraZeneca & Intel
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), AstraZeneca PLC (AZN) and Intel Corporation (INTC).
LLY Down as Patients Regain Weight After Stopping Zepbound
by Zacks Equity Research
Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B
by Zacks Equity Research
AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
by Zacks Equity Research
After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
by Zacks Equity Research
Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
by Zacks Equity Research
Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
by Zacks Equity Research
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
by Zacks Equity Research
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study
by Zacks Equity Research
Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
by Zacks Equity Research
Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.
Novo Nordisk (NVO) to Expand Manufacturing Site in France
by Zacks Equity Research
Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.
Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know
by Zacks Equity Research
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.